Communication autocrine : Questions médicales fréquentes
Nom anglais: Autocrine Communication
Descriptor UI:D019898
Tree Number:G04.085.100
Termes MeSH sélectionnés :
Cholangiocarcinoma
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Communication autocrine : Questions médicales les plus fréquentes",
"headline": "Communication autocrine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Communication autocrine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-27",
"dateModified": "2025-04-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Communication autocrine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Communication cellulaire",
"url": "https://questionsmedicales.fr/mesh/D002450",
"about": {
"@type": "MedicalCondition",
"name": "Communication cellulaire",
"code": {
"@type": "MedicalCode",
"code": "D002450",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G04.085"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Communication autocrine",
"alternateName": "Autocrine Communication",
"code": {
"@type": "MedicalCode",
"code": "D019898",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Mei Chen",
"url": "https://questionsmedicales.fr/author/Mei%20Chen",
"affiliation": {
"@type": "Organization",
"name": "Department of Dermatology and the USC-Norris Comprehensive Cancer Center, University of Southern California Keck Medical Centre, Los Angeles, CA, 90033, USA."
}
},
{
"@type": "Person",
"name": "Hamideh P Fallah",
"url": "https://questionsmedicales.fr/author/Hamideh%20P%20Fallah",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, Alberta, T2N 1N4, Canada."
}
},
{
"@type": "Person",
"name": "Hamid R Habibi",
"url": "https://questionsmedicales.fr/author/Hamid%20R%20Habibi",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, Alberta, T2N 1N4, Canada. Electronic address: Habibi@ucalgary.ca."
}
},
{
"@type": "Person",
"name": "Michael Downes",
"url": "https://questionsmedicales.fr/author/Michael%20Downes",
"affiliation": {
"@type": "Organization",
"name": "Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037."
}
},
{
"@type": "Person",
"name": "Ronald M Evans",
"url": "https://questionsmedicales.fr/author/Ronald%20M%20Evans",
"affiliation": {
"@type": "Organization",
"name": "Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Current epidemiology of cholangiocarcinoma in Western countries.",
"datePublished": "2022-08-14",
"url": "https://questionsmedicales.fr/article/35977611",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jhep.2022.07.022"
}
},
{
"@type": "ScholarlyArticle",
"name": "Nivolumab for treating patients with occupational cholangiocarcinoma.",
"datePublished": "2022-08-08",
"url": "https://questionsmedicales.fr/article/35793385",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jhbp.1215"
}
},
{
"@type": "ScholarlyArticle",
"name": "Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma.",
"datePublished": "2022-09-20",
"url": "https://questionsmedicales.fr/article/36123506",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12072-022-10419-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Characteristics and clinical outcomes in young-onset cholangiocarcinoma.",
"datePublished": "2023-05-22",
"url": "https://questionsmedicales.fr/article/37212509",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cam4.6063"
}
},
{
"@type": "ScholarlyArticle",
"name": "Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma.",
"datePublished": "2023-03-01",
"url": "https://questionsmedicales.fr/article/36936931",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1142690"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes physiologiques cellulaires",
"item": "https://questionsmedicales.fr/mesh/D002468"
},
{
"@type": "ListItem",
"position": 3,
"name": "Communication cellulaire",
"item": "https://questionsmedicales.fr/mesh/D002450"
},
{
"@type": "ListItem",
"position": 4,
"name": "Communication autocrine",
"item": "https://questionsmedicales.fr/mesh/D019898"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Communication autocrine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Communication autocrine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Communication autocrine",
"description": "Comment diagnostiquer une communication autocrine ?\nQuels tests sont utilisés pour évaluer la communication autocrine ?\nY a-t-il des marqueurs spécifiques pour la communication autocrine ?\nLa communication autocrine est-elle visible par imagerie ?\nQuels sont les signes d'une dérégulation autocrine ?",
"url": "https://questionsmedicales.fr/mesh/D019898?mesh_terms=Cholangiocarcinoma&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Communication autocrine",
"description": "Quels symptômes indiquent une communication autocrine anormale ?\nLa communication autocrine affecte-t-elle le métabolisme ?\nY a-t-il des symptômes spécifiques liés à l'autocrine dans le cancer ?\nComment la communication autocrine influence-t-elle l'immunité ?\nDes symptômes neurologiques peuvent-ils être liés à l'autocrine ?",
"url": "https://questionsmedicales.fr/mesh/D019898?mesh_terms=Cholangiocarcinoma&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Communication autocrine",
"description": "Comment prévenir les dérégulations autocrines ?\nY a-t-il des mesures préventives spécifiques pour le cancer ?\nL'exercice physique aide-t-il à réguler l'autocrine ?\nLe stress influence-t-il la communication autocrine ?\nDes compléments alimentaires peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D019898?mesh_terms=Cholangiocarcinoma&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Communication autocrine",
"description": "Quels traitements ciblent la communication autocrine ?\nLes médicaments peuvent-ils moduler la communication autocrine ?\nY a-t-il des traitements spécifiques pour le cancer liés à l'autocrine ?\nComment la thérapie génique influence-t-elle l'autocrine ?\nLes traitements hormonaux affectent-ils la communication autocrine ?",
"url": "https://questionsmedicales.fr/mesh/D019898?mesh_terms=Cholangiocarcinoma&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Communication autocrine",
"description": "Quelles complications peuvent résulter d'une communication autocrine anormale ?\nLa communication autocrine peut-elle entraîner des troubles métaboliques ?\nY a-t-il des risques d'inflammation chronique ?\nComment la communication autocrine affecte-t-elle le cancer ?\nDes complications neurologiques sont-elles possibles ?",
"url": "https://questionsmedicales.fr/mesh/D019898?mesh_terms=Cholangiocarcinoma&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Communication autocrine",
"description": "Quels sont les facteurs de risque de dérégulation autocrine ?\nL'alimentation influence-t-elle la communication autocrine ?\nLe stress est-il un facteur de risque ?\nY a-t-il des prédispositions génétiques ?\nL'exposition à des produits chimiques est-elle un risque ?",
"url": "https://questionsmedicales.fr/mesh/D019898?mesh_terms=Cholangiocarcinoma&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une communication autocrine ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests biologiques et des analyses de signalisation cellulaire."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la communication autocrine ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de culture cellulaire et des dosages de cytokines peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour la communication autocrine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des marqueurs comme les récepteurs de cytokines peuvent indiquer une communication autocrine."
}
},
{
"@type": "Question",
"name": "La communication autocrine est-elle visible par imagerie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle n'est généralement pas visible par imagerie, mais des techniques avancées peuvent aider."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'une dérégulation autocrine ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes incluent une croissance cellulaire anormale ou une inflammation persistante."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une communication autocrine anormale ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes peuvent inclure des douleurs, des inflammations ou des tumeurs."
}
},
{
"@type": "Question",
"name": "La communication autocrine affecte-t-elle le métabolisme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut influencer le métabolisme cellulaire et provoquer des déséquilibres."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques liés à l'autocrine dans le cancer ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme la fatigue et la perte de poids peuvent être présents."
}
},
{
"@type": "Question",
"name": "Comment la communication autocrine influence-t-elle l'immunité ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut moduler la réponse immunitaire, entraînant une inflammation ou une immunosuppression."
}
},
{
"@type": "Question",
"name": "Des symptômes neurologiques peuvent-ils être liés à l'autocrine ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent survenir en raison de la signalisation autocrine."
}
},
{
"@type": "Question",
"name": "Comment prévenir les dérégulations autocrines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et un mode de vie sain peuvent aider à prévenir ces dérégulations."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives spécifiques pour le cancer ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter les carcinogènes et maintenir un poids santé sont des mesures préventives."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il à réguler l'autocrine ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut moduler la signalisation autocrine et améliorer la santé cellulaire."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il la communication autocrine ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut perturber la communication autocrine et affecter la santé."
}
},
{
"@type": "Question",
"name": "Des compléments alimentaires peuvent-ils aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains compléments, comme les oméga-3, peuvent moduler la communication autocrine."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent la communication autocrine ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies ciblées et des inhibiteurs de signalisation peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils moduler la communication autocrine ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent inhiber ou stimuler la signalisation autocrine."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements spécifiques pour le cancer liés à l'autocrine ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements comme les anticorps monoclonaux ciblent souvent la communication autocrine dans le cancer."
}
},
{
"@type": "Question",
"name": "Comment la thérapie génique influence-t-elle l'autocrine ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique peut corriger des dérégulations dans la communication autocrine."
}
},
{
"@type": "Question",
"name": "Les traitements hormonaux affectent-ils la communication autocrine ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements hormonaux peuvent influencer la signalisation autocrine dans certaines pathologies."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent résulter d'une communication autocrine anormale ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des cancers, des maladies auto-immunes et des inflammations chroniques."
}
},
{
"@type": "Question",
"name": "La communication autocrine peut-elle entraîner des troubles métaboliques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une dérégulation peut provoquer des troubles métaboliques comme le diabète."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques d'inflammation chronique ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une communication autocrine anormale peut entraîner une inflammation chronique."
}
},
{
"@type": "Question",
"name": "Comment la communication autocrine affecte-t-elle le cancer ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut favoriser la croissance tumorale et la résistance aux traitements anticancéreux."
}
},
{
"@type": "Question",
"name": "Des complications neurologiques sont-elles possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dérégulations peuvent entraîner des troubles neurologiques et cognitifs."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de dérégulation autocrine ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, l'obésité, le tabagisme et l'exposition à des toxines."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle la communication autocrine ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en sucres et graisses peut perturber la signalisation autocrine."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut augmenter le risque de dérégulation autocrine."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mutations génétiques peuvent prédisposer à des dérégulations autocrines."
}
},
{
"@type": "Question",
"name": "L'exposition à des produits chimiques est-elle un risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des produits chimiques toxiques peut augmenter le risque de dérégulation."
}
}
]
}
]
}
Cholangiocarcinomas are cancers arising from bile ducts, either found within the liver (intrahepatic) or outside the liver (extrahepatic). In Western countries, deaths due to intrahepatic cancers are ...
Tanaka et al. previously reported a case in which nivolumab for recurrent occupational cholangiocarcinoma resulted in complete response persisting for 26 months after discontinuation. Afterward, in th...
Integration of HBV DNA into the human genome could progressively contribute to hepatocarcinogenesis. Both intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular-cholangiocarcinoma (CHC) are...
41 patients with ICC and 20 patients with CHC were recruited in the study. We conducted HIVID analysis on these 61 samples to identify HBV integration sites in both the tumor tissues and adjacent non-...
We detected 493 HBV integration sites in ICC patients, of which 417 were from tumor samples and 76 were from non-tumor samples. And 246 HBV integration sites were detected in CHC patients, of which 15...
Comparative analysis demonstrates numerous newly discovered mutational events in ICC and CHC resulting from HBV insertions in the host genome. Our study provides an in-depth biological and clinical in...
While the incidence of cholangiocarcinoma is rising, little is known about young-onset disease. We compared clinical characteristics and outcomes between patients with young-onset cholangiocarcinoma, ...
We used the National Cancer Database to identify patients with young-onset cholangiocarcinoma (n = 2520) and typical-onset cholangiocarcinoma (n = 23,826). We compared the frequency of demographic and...
When compared to patients with typical-onset disease (median age 68 years), patients with young-onset cholangiocarcinoma (median age 44 years) were more likely to be non-White (35.0% vs. 27.4%, p < 0....
Patients with young-onset cholangiocarcinoma may represent a demographically and clinically distinct group from those with more typical-onset disease....
Cholangiocarcinoma (CCA) is a rare and aggressive type of malignant tumor. In the past few years, there has been an increase in the incidence of CCA. Surgery is the only effective treatment but is onl...
It is difficult to directly obtain pathological diagnosis of perihilar cholangiocarcinoma (pCCA). Analysis of bile in the pCCA microenvironment, based on metabolomics and statistical methods, can help...
Cholangiocarcinoma (CHOL) is one of the most aggressive tumors worldwide and cannot be effectively treated by conventional and novel treatments, including immune checkpoint blockade therapy. The mRNA ...
In addition to conditioning measures in liver surgery, perioperative anti-tumor therapy is becoming increasingly more important in cholangiocarcinoma (CCA)....
Systematic literature review on the status of multimodal and in particular neoadjuvant therapy for CCA....
Literature overview of the current scientific original and review articles....
Resection and rarely also liver transplantation are still the only curative treatment approaches for CCA in the non-distant metastatic stage; however, long-term results, e.g. in node positive tumors, ...
There is a high potential for the use of multimodal therapy in CCA, which could further increase in the near future as a result of new therapeutic agents. Due to the lack of evidence clear recommendat...
Hepatocellular carcinoma and intrahepatic cholangiocarcinoma are the two most common primary malignant tumors of the liver. The similarities and variations in imaging characteristics that may aid in d...
Cholangiocarcinoma (CCA) is an invasive cancer accounting for <1% of all cancers and 10-15% of primary liver cancers. Intrahepatic CCA (iCCA) is associated with poor survival rates and high post-surgi...